{"gene":"TNFRSF6B","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1999,"finding":"TR6/DcR3 specifically binds two TNF-family ligands, LIGHT and FasL/CD95L, as demonstrated by immunoprecipitation with histidine-tagged recombinant TR6 and confirmed by flow cytometry on LIGHT-transfected HEK 293 EBNA cells. TR6 inhibits LIGHT-induced cytotoxicity in HT29 cells by blocking LIGHT interactions with HVEM/TR2 and LTβR.","method":"Immunoprecipitation, flow cytometry, cytotoxicity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding confirmed by two orthogonal methods (IP and flow cytometry), functional inhibition demonstrated, replicated in multiple cell lines","pmids":["10318773"],"is_preprint":false},{"year":2002,"finding":"TL1A is a third ligand for DcR3/TR6 (and for signaling receptor DR3). TR6-Fc protein binds TL1A and antagonizes TL1A-induced NF-κB activation and apoptosis in DR3-expressing cell lines, demonstrating DcR3 decoy function against TL1A.","method":"Ligand binding assay, NF-κB reporter assay, apoptosis assay, TR6-Fc competition","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional antagonism demonstrated by multiple assays, TR6-Fc competition confirms direct ligand neutralization","pmids":["11911831"],"is_preprint":false},{"year":2001,"finding":"TR6-Fc recombinant protein binds human LIGHT expressed on 293 cells or activated T cells and competes with the LIGHT receptor TR2 for LIGHT binding, as shown by flow cytometry and immunoprecipitation. TR6 downregulates CTL activity and modulates lymphokine production in vitro and in vivo.","method":"Flow cytometry, immunoprecipitation, CTL assay, graft-versus-host mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (flow cytometry, IP, in vivo model) confirming competitive antagonism of LIGHT:TR2 interaction","pmids":["11390428"],"is_preprint":false},{"year":2001,"finding":"TR6 binds FasL and blocks FasL-mediated cell killing in vitro in multiple cell systems (human hepatocytes, HT-29, Jurkat cells) and in vivo in a mouse fulminant hepatitis model where pretreatment with TR6 blocked FasL-induced mortality. Human TR6 cross-reacts with membrane-bound mouse FasL. Binding of human TR6 to human FasL was confirmed by BIAcore surface plasmon resonance.","method":"BIAcore binding assay, cytotoxicity assays, in vivo mouse hepatitis model","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding measured by SPR, functional inhibition in multiple cell systems and confirmed in vivo","pmids":["11408521"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of unliganded DcR3 ectodomain and its complex with TL1A reveals that DcR3 interacts with invariant backbone and side-chain atoms in the membrane-proximal half of TL1A. Mutagenesis and biochemical studies show that the same interface supports recognition of FasL, LIGHT, and TL1A, while antideterminant features prevent binding to other TNF superfamily members. This is a unique mode of TNF:TNFR interaction enabling broad ligand specificity.","method":"X-ray crystallography, site-directed mutagenesis, biochemical binding assays","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure combined with mutagenesis and biochemical validation, mechanistically defines the basis for DcR3 multi-ligand recognition","pmids":["21300286"],"is_preprint":false},{"year":2014,"finding":"Crystal structure of LIGHT and the LIGHT:DcR3 complex reveals the structural basis for DcR3-mediated neutralization of LIGHT and its inhibition of LIGHT interactions with HVEM and LTβR. Structure-guided LIGHT mutants with altered affinities for DcR3 and HVEM were generated, validating the binding interface.","method":"X-ray crystallography, site-directed mutagenesis, binding affinity assays","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure with mutagenesis validation, mechanistically defining LIGHT:DcR3 binding mode","pmids":["25087510"],"is_preprint":false},{"year":2016,"finding":"Crystal structure of FasL in complex with DcR3 reveals that DcR3 recognizes invariant main-chain and conserved side-chain functionalities of FasL, consistent with the recognition paradigm seen in TL1A:DcR3 and LIGHT:DcR3 structures. Recombinant DcR3 efficiently inhibits FasL-induced Jurkat cell apoptosis.","method":"X-ray crystallography, apoptosis assay","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure with functional validation of FasL:DcR3 inhibition of apoptosis","pmids":["27806260"],"is_preprint":false},{"year":2003,"finding":"DcR3 is proteolytically cleaved between R218 and A219 (identified by mass spectrometry and N-terminal sequencing) to yield DcR3(1–218), which retains LIGHT-binding activity but loses FasL-binding ability. Engineering of R218Q substitution (FLINT/LY498919) prevents proteolytic cleavage and restores activity against both FasL and LIGHT in vitro and in vivo.","method":"Mass spectrometry, N-terminal sequencing, in vitro binding assay, site-directed mutagenesis, in vivo pharmacokinetic study","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mass spectrometry identification of cleavage site, mutagenesis rescue, confirmed in vitro and in vivo; single lab but multiple orthogonal methods","pmids":["12566095"],"is_preprint":false},{"year":2004,"finding":"DcR3 induces osteoclast formation from human monocytes, murine RAW264.7 macrophages, and bone marrow cells via 'reverse signaling'. DcR3-differentiated cells exhibit osteoclast characteristics (polynuclear morphology, bone resorption, TRAP, CD51/61, MMP-9). DcR3 treatment induces TNF-α release through ERK and p38 MAPK signaling; the osteoclastogenic effect is abrogated by TNFR-Fc, confirming TNF-α as the downstream mediator.","method":"Cell differentiation assay, bone resorption assay, Western blotting for MAPK signaling, TNFR-Fc blocking experiment","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean loss-of-function (blocking) with specific phenotypic readout and pathway placement (ERK/p38 → TNF-α → osteoclastogenesis), single lab","pmids":["15002040"],"is_preprint":false},{"year":2007,"finding":"DcR3 induces apoptosis in dendritic cells by binding heparan sulfate proteoglycans (HSPG) on DCs via its heparin-binding domain (HBD), activating PKC-δ and JNK, upregulating DR5, and recruiting FADD to form a death-inducing signaling complex (DISC). HBD.Fc fusion protein alone recapitulates this effect, demonstrating that HSPG cross-linking is sufficient to trigger the apoptotic cascade.","method":"Apoptosis assay, Western blotting (PKC-δ, JNK, DR5, FADD), DISC immunoprecipitation, HBD.Fc domain dissection experiment","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — DISC co-IP, domain dissection with HBD.Fc, multiple downstream signaling nodes validated, single lab but multiple orthogonal methods","pmids":["18006694"],"is_preprint":false},{"year":2003,"finding":"TR6/DcR3 inhibits T cell chemotaxis toward CXCL12/SDF-1α in vitro and in vivo. Solid-phase TR6-Fc or anti-LIGHT mAb similarly inhibit chemotaxis, implicating LIGHT reverse signaling. Mechanistically, TR6 pretreatment prevents Cdc42 activation, p38 MAPK phosphorylation, actin polymerization, and pseudopodium formation in T cells.","method":"Transwell chemotaxis assay, Cdc42 activation assay, p38 MAPK phosphorylation assay, actin polymerization assay, in vivo mouse chemotaxis model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal mechanistic readouts (Cdc42, p38, actin, pseudopodium) with in vivo confirmation, single lab","pmids":["14500635"],"is_preprint":false},{"year":2003,"finding":"TR6 secreted by PBMC inhibits actin polymerization and pseudopodium formation in T cells upon mitogen stimulation, suppressing T cell aggregation induced by alloantigens, anti-CD3, or PHA in a soluble or solid-phase manner.","method":"Actin polymerization assay, T cell aggregation assay (PBMC stimulation with alloantigens/anti-CD3/PHA), TR6-Fc solid-phase treatment","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple aggregation assays, actin polymerization measured, single lab, complementary to PMID 14500635","pmids":["12761893"],"is_preprint":false},{"year":2009,"finding":"DcR3 protects beta islet cells from apoptosis induced by FasL, LIGHT, and TL1A. DNA microarray analysis of DcR3 transgenic islets revealed that Adcyap1 is upregulated >700-fold and Bank1 is downregulated 50-fold after cytokine assault. Forced overexpression of Adcyap1 or knockdown of Bank1 in insulinoma NIT-1 cells each independently protected against cytokine-triggered apoptosis, identifying novel downstream mediators.","method":"DNA microarray, transgenic mouse model, siRNA knockdown, plasmid overexpression, apoptosis assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DNA microarray combined with functional validation (siRNA + overexpression) for downstream mediators, single lab","pmids":["20007581"],"is_preprint":false},{"year":2009,"finding":"DcR3-Fc protects THP-1 macrophages from apoptosis by upregulating integrin α4 (VLA-4), promoting macrophage aggregate formation. Anti-VLA4 antibody blocks both the anti-apoptotic effect and aggregate formation induced by DcR3-Fc, demonstrating that increased α4 integrin expression is the mechanism of DcR3-mediated macrophage survival.","method":"Apoptosis assay (CHX-induced), integrin expression by Western blot/flow cytometry, anti-VLA4 antibody blocking experiment, aggregate formation assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody blocking confirms mechanistic link between DcR3, α4 integrin upregulation, and anti-apoptotic effect; single lab","pmids":["19748482"],"is_preprint":false},{"year":2011,"finding":"DcR3 binds to TL1A expressed on rheumatoid synovial fibroblasts (RA-FLS) and negatively regulates cytokine-induced cell proliferation. This DcR3-TL1A signaling represents a 'reverse signaling' mode where DcR3 acts as a ligand rather than a decoy receptor.","method":"Cell proliferation assay, binding assay in RA-FLS, cytokine stimulation experiments","journal":"International journal of molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, limited mechanistic depth in abstract, proliferation assay alone","pmids":["21537832"],"is_preprint":false},{"year":2009,"finding":"DcR3 suppresses Th17 immune responses; DcR3.Fc treatment of PLP-specific lymph node cells suppresses IFN-γ and IL-17 production and reduces proportion of Th17 cells. DcR3.Fc treatment of CD4+ T cells with defective FasL did not suppress IL-17, demonstrating that DcR3-mediated IL-17 suppression depends on disruption of Fas-FasL interactions.","method":"Lymph node cell culture, cytokine ELISA, flow cytometry (Th17 proportion), FasL-defective T cell experiment","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FasL-defective T cell control establishes mechanism; multiple assays; single lab","pmids":["19269042"],"is_preprint":false},{"year":2010,"finding":"DcR3 inhibits p53-dependent apoptosis in lung cancer cells. Knockdown of DcR3 in p53-expressing cells sensitizes them to γ-irradiation by inducing p53-dependent Fas-mediated apoptosis pathway. In p53-deficient H1299 cells, DcR3 knockdown had no effect on survival after irradiation, but introduction of p53 restored sensitivity. Overexpression of DcR3 increased survival of radiosensitive cells.","method":"siRNA knockdown, clonogenic survival assay, p53 re-introduction experiment, Western blot","journal":"International journal of radiation biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established via p53-null vs. p53-rescue experiment, multiple cell lines tested; single lab","pmids":["20597837"],"is_preprint":false},{"year":2015,"finding":"DcR3 attenuates influenza A virus-induced macrophage activation by inactivating PKC-α and activating STK10 (a negative regulator of cell migration), thereby suppressing ERK and JNK activation. Proteome-wide phosphoproteomic mapping identified these kinase targets. DcR3-transgenic mice show reduced pulmonary infiltration and cytokine levels, and recombinant HBD.Fc (heparin-binding domain of DcR3) recapitulates protection, indicating HSPG-dependent signaling.","method":"Phosphoproteomic mapping, Western blot (ERK, JNK, PKC-α, STK10), DcR3 transgenic mouse, HBD.Fc domain experiment","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomic mapping with in vivo transgenic confirmation and HBD.Fc domain dissection; single lab","pmids":["25940317"],"is_preprint":false},{"year":2017,"finding":"DcR3 mediates neuroprotection in an Alzheimer's disease model by interacting with heparan sulfate proteoglycans (HSPGs) and activating IL-4+YM1+ M2a-like microglia, reducing Aβ-induced proinflammatory cytokines and promoting phagocytosis. Co-immunoprecipitation confirmed DcR3-HSPG interaction in brain tissue of APP/DcR3 transgenic mice.","method":"APP/DcR3 transgenic mouse cross, immunostaining, ELISA, qPCR, immunoprecipitation (DcR3-HSPG), in vitro macrophage polarization assay","journal":"Molecular neurodegeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IP confirms HSPG interaction in vivo, multiple readouts (behavioral, pathological, molecular); single lab","pmids":["28438208"],"is_preprint":false},{"year":2012,"finding":"DcR3 binds to epithelial ovarian cancer cells via heparan sulfate proteoglycans (HSPGs); binding is inhibited by heparin and heparinase treatment. DcR3 binding via HSPGs (Syndecan-2 and CD44v3) alters platinum chemotherapy responsiveness and modulates BRCA1 expression (increase in SKOV-3/OVCAR-3, decrease in CaOV3), affecting DNA repair pathways.","method":"Heparin/heparinase competition binding assay, RT-PCR array, Western blot (BRCA1), MTT cell viability assay","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic binding inhibition with heparin/heparinase validates HSPG-dependent interaction; BRCA1 confirmed by Western blot; single lab","pmids":["22583667"],"is_preprint":false},{"year":2013,"finding":"Missense mutations in DcR3 (T56I and H122Y) identified in SLE patients exhibit altered binding kinetics to FasL and significantly increase lymphocyte proliferation compared to wild-type DcR3 protein, demonstrating gain-of-function mutations that perturb receptor-ligand interaction.","method":"DNA sequencing, recombinant mutant protein production, FasL binding kinetics assay, lymphocyte proliferation assay","journal":"The Journal of rheumatology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — recombinant protein mutagenesis with binding kinetics and functional readout; single lab, limited sample size","pmids":["23729807"],"is_preprint":false},{"year":2018,"finding":"DcR3 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of gastric cancer cells via the PI3K/AKT/GSK-3β/β-catenin signaling pathway. DcR3 knockdown reduces p-AKT, p-GSK-3β, and β-catenin levels; DcR3 enhances N-cadherin and Vimentin expression while decreasing E-cadherin.","method":"shRNA stable knockdown, proliferation/invasion/migration assays, Western blot (PI3K/AKT pathway components, EMT markers)","journal":"OncoTargets and therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable shRNA knockdown with multiple functional assays and pathway Western blots; single lab","pmids":["30050309"],"is_preprint":false},{"year":2016,"finding":"DcR3 is essential for TGF-β3/SMAD-mediated epithelial-mesenchymal transition (EMT) in colorectal cancer cells. DcR3 overexpression enhances CRC proliferation and migration in vitro and tumorigenesis in vivo; DcR3 knockdown attenuates CRC tumorigenesis and metastasis in vivo. DcR3 expression correlates with TGF-β3/SMAD-EMT signaling components.","method":"shRNA knockdown, DcR3 overexpression, in vitro proliferation/migration assays, in vivo xenograft model, Western blot (SMAD pathway, EMT markers)","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional genetic manipulation (KD and OE), in vivo confirmation, pathway Western blots; single lab","pmids":["27764793"],"is_preprint":false},{"year":2019,"finding":"DcR3 promotes pancreatic cancer proliferation and invasion through a positive feedback loop: DcR3 activates STAT1 phosphorylation, leading to increased IRF1, which then increases DcR3 transcriptional activity. DcR3 also promotes CEACAM1 expression through activated IRF1.","method":"Loss-of-function and gain-of-function experiments, Western blot (STAT1 phosphorylation, IRF1), transcriptional reporter assay, in vitro proliferation/invasion assays, in vivo tumor growth assay","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional genetic manipulation, transcriptional reporter confirms feedback loop, in vivo confirmation; single lab","pmids":["31911850"],"is_preprint":false},{"year":2019,"finding":"DcR3 overexpression in hepatocellular carcinoma is mediated by the TGFβ3-Smad-Sp1 signaling pathway, which directly targets DcR3 promoter regions. DcR3 overexpression promotes Th2 and Treg cell differentiation while inhibiting Th1 cell differentiation; DcR3 knockdown restores CD4+ T cell immunity.","method":"Promoter analysis, ChIP/reporter assay (TGFβ3-Smad-Sp1 targeting DcR3 promoter), T cell differentiation assays, DcR3 knockdown and overexpression","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter targeting validated, T cell functional assays; single lab, limited method detail in abstract","pmids":["31409774"],"is_preprint":false},{"year":2017,"finding":"DcR3 promotes hepatoma cell migration by downregulating E-cadherin expression and activating NF-κB signaling (IκBα degradation and p65 nuclear translocation). DcR3 expression inversely correlates with E-cadherin expression in liver cancer tissues.","method":"Immunofluorescence, flow cytometry, Western blot (E-cadherin, IκBα, p65), immunohistochemistry of clinical samples","journal":"Oncology reports","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — multiple methods but largely correlative; NF-κB activation shown by Western blot without definitive causal rescue experiment","pmids":["28560426"],"is_preprint":false},{"year":2018,"finding":"Up-regulation of DcR3 by microbial toxins (LPS, LTA, zymosan) in HUVECs proceeds through the NF-κB signaling pathway; NF-κB inhibitor PDTC decreased DcR3 expression, while JNK (SP600125) and p38 MAPK (SB203580) inhibitors had no effect on DcR3 mRNA or protein levels.","method":"RT-PCR, ELISA, pharmacological pathway inhibition (PDTC, SP600125, SB203580)","journal":"BMC biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway specificity confirmed by selective inhibitors, negative controls (JNK/p38 inhibitors) establish specificity for NF-κB; single lab","pmids":["30587127"],"is_preprint":false},{"year":2024,"finding":"ZNF37A binds to the TNFRSF6B/DcR3 promoter region and suppresses its transcriptional activity. Reduced ZNF37A expression induces chemoradiation resistance by inhibiting apoptosis in colorectal cancer cells; TNFRSF6B knockdown restores sensitivity to chemoradiotherapy.","method":"Promoter binding assay, transcriptional activity assay, shRNA knockdown, genome-wide expression profiling, functional apoptosis/survival assays","journal":"Translational oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding and transcriptional repression demonstrated, functional rescue by TNFRSF6B knockdown; single lab","pmids":["39571490"],"is_preprint":false},{"year":2011,"finding":"DcR3 induces chondrocyte proliferation in osteoarthritis chondrocytes via ERK (MAPK) signaling specifically. DcR3-Fc-induced proliferation is blocked by MEK1/2 inhibitor PD098059 and by anti-FasL blocking antibody, but not by anti-LIGHT or anti-TL1A antibodies, establishing that the proliferative effect is mediated through DcR3 binding to FasL and ERK activation.","method":"WST proliferation assay, Western blot (ERK, p38, JNK phosphorylation), MEK inhibitor, ligand-blocking antibodies, TUNEL/caspase Western blot (apoptosis)","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inhibitor and blocking antibody experiments establish pathway specificity; single lab","pmids":["21420502"],"is_preprint":false}],"current_model":"DcR3/TNFRSF6B is a secreted, soluble decoy receptor that lacks transmembrane and death domains; it neutralizes three TNF-family ligands (FasL, LIGHT, and TL1A) by competitively binding their membrane-proximal interface (established by crystal structures of all three complexes), thereby blocking apoptosis, T-cell activation, and immune responses mediated by these ligands. Beyond decoy function, DcR3 engages heparan sulfate proteoglycans (HSPGs) on target cells to trigger 'reverse signaling'—activating PKC-δ/JNK in dendritic cells to induce DR5-FADD DISC formation and apoptosis, or activating ERK/p38 MAPK in monocytes to drive osteoclastogenesis via TNF-α, or activating STK10/inhibiting PKC-α to suppress macrophage migration; in T cells, DcR3 prevents Cdc42 activation and actin polymerization to inhibit chemotaxis and aggregation; in cancer cells, it engages PI3K/AKT/GSK-3β/β-catenin, TGF-β3/SMAD, and STAT1/IRF1 pathways to promote EMT, proliferation, and immune escape, with its own expression regulated by NF-κB, TGFβ3-Smad-Sp1, and the STAT1/IRF1 feedback loop. Proteolytic cleavage at R218-A219 generates a fragment that retains LIGHT binding but loses FasL binding, and the R218Q mutation (FLINT) stabilizes the intact molecule."},"narrative":{"mechanistic_narrative":"TNFRSF6B (DcR3/TR6) is a secreted soluble decoy receptor of the TNF receptor superfamily that neutralizes three TNF-family ligands—FasL/CD95L, LIGHT, and TL1A—to dampen apoptosis, cytotoxic T-cell activity, and inflammatory signaling [PMID:10318773, PMID:11911831, PMID:11390428, PMID:11408521]. Crystal structures of DcR3 bound to TL1A, LIGHT, and FasL show that it engages invariant main-chain and conserved side-chain atoms in the membrane-proximal half of each ligand, a single shared interface that explains its broad specificity while antideterminants exclude other TNF superfamily members [PMID:21300286, PMID:25087510, PMID:27806260]; in functional terms this lets DcR3-Fc competitively block LIGHT binding to HVEM/TR2 and LTβR, antagonize TL1A-induced NF-κB activation and DR3 apoptosis, and inhibit FasL-mediated killing in vitro and in vivo [PMID:10318773, PMID:11911831, PMID:11408521]. Proteolytic cleavage between R218 and A219 yields a fragment that retains LIGHT binding but loses FasL binding, and the R218Q (FLINT) substitution blocks cleavage to preserve activity against both ligands [PMID:12566095]. Beyond decoy function, DcR3 acts as a ligand that engages heparan sulfate proteoglycans on target cells to trigger 'reverse signaling': HSPG cross-linking by its heparin-binding domain activates PKC-δ/JNK to upregulate DR5 and assemble a FADD-containing DISC in dendritic cells, drives ERK/p38-dependent TNF-α release to promote osteoclastogenesis in monocytes, and modulates macrophage and microglial activation [PMID:15002040, PMID:18006694, PMID:25940317, PMID:28438208]. In T cells DcR3/LIGHT reverse signaling blocks Cdc42 activation, p38 phosphorylation, and actin polymerization to suppress chemotaxis and aggregation [PMID:14500635, PMID:12761893]. In cancer, DcR3 promotes proliferation, migration, and EMT through PI3K/AKT/GSK-3β/β-catenin, TGF-β3/SMAD, and a self-reinforcing STAT1/IRF1 loop, and its own expression is controlled by NF-κB, TGFβ3-Smad-Sp1, and transcriptional repression by ZNF37A [PMID:30050309, PMID:27764793, PMID:31911850, PMID:31409774, PMID:30587127, PMID:39571490]. Gain-of-function DcR3 missense mutations (T56I, H122Y) with altered FasL binding and increased lymphocyte proliferation have been identified in SLE patients [PMID:23729807].","teleology":[{"year":1999,"claim":"Established DcR3 as a soluble decoy that binds TNF-family ligands rather than transducing signal, by showing it captures LIGHT and FasL and neutralizes LIGHT cytotoxicity.","evidence":"Immunoprecipitation, flow cytometry on LIGHT-transfected cells, and cytotoxicity blockade in HT29 cells","pmids":["10318773"],"confidence":"High","gaps":["Did not resolve the structural basis of multi-ligand recognition","TL1A not yet identified as a ligand"]},{"year":2001,"claim":"Defined the competitive mechanism against LIGHT and FasL and demonstrated immunological consequences, showing DcR3 displaces LIGHT from TR2 and blocks FasL-induced killing in vivo.","evidence":"Flow cytometry/IP competition with TR2, BIAcore SPR for FasL binding, CTL assays, and mouse GvHD and fulminant hepatitis models","pmids":["11390428","11408521"],"confidence":"High","gaps":["Atomic interface not yet defined","Whether one binding site accommodates all ligands unknown"]},{"year":2002,"claim":"Identified TL1A as a third DcR3 ligand and showed DcR3-Fc antagonizes TL1A-driven NF-κB and apoptosis via the DR3 axis, expanding the decoy's ligand repertoire.","evidence":"Ligand binding, NF-κB reporter and apoptosis assays with TR6-Fc competition in DR3-expressing lines","pmids":["11911831"],"confidence":"High","gaps":["Did not address reverse signaling through TL1A on ligand-bearing cells"]},{"year":2003,"claim":"Revealed that proteolytic cleavage at R218-A219 differentially abolishes FasL but not LIGHT binding, and that the R218Q mutation stabilizes the intact, dually active molecule—pharmacologically relevant for the FLINT therapeutic.","evidence":"Mass spectrometry, N-terminal sequencing, mutagenesis rescue, and in vivo pharmacokinetics","pmids":["12566095"],"confidence":"High","gaps":["Identity of the responsible protease not established","Physiological context regulating cleavage unknown"]},{"year":2003,"claim":"Established that DcR3 acts as a ligand triggering reverse signaling in T cells, suppressing chemotaxis and aggregation by blocking Cdc42, p38, and actin polymerization.","evidence":"Transwell chemotaxis, Cdc42 activation, p38 phosphorylation, actin polymerization assays with anti-LIGHT mAb and in vivo chemotaxis model","pmids":["14500635","12761893"],"confidence":"High","gaps":["Receptor on T cells mediating reverse signaling not fully defined","Link between LIGHT engagement and Cdc42 inhibition incomplete"]},{"year":2007,"claim":"Defined HSPG cross-linking by the heparin-binding domain as a decoy-independent mechanism, showing DcR3 induces DC apoptosis via PKC-δ/JNK, DR5 upregulation, and FADD-DISC formation.","evidence":"DISC co-IP, signaling Western blots, and HBD.Fc domain-dissection apoptosis assays","pmids":["18006694"],"confidence":"High","gaps":["Specific HSPG species engaged in DCs not identified","How HSPG binding activates PKC-δ mechanistically unresolved"]},{"year":2004,"claim":"Showed DcR3 reverse signaling drives osteoclastogenesis, placing ERK/p38-induced TNF-α as the downstream effector of monocyte differentiation.","evidence":"Differentiation and bone resorption assays, MAPK Western blots, and TNFR-Fc blockade","pmids":["15002040"],"confidence":"Medium","gaps":["Receptor coupling ERK/p38 to TNF-α not defined","Single lab"]},{"year":2009,"claim":"Extended DcR3 cytoprotection to islet, macrophage, and Th17 contexts, identifying distinct effectors (Adcyap1/Bank1, α4 integrin) and confirming FasL-dependence of IL-17 suppression.","evidence":"Transgenic islet microarray with siRNA/overexpression validation, anti-VLA4 blocking in macrophages, and FasL-defective T-cell controls","pmids":["20007581","19748482","19269042"],"confidence":"Medium","gaps":["Whether effects are decoy- vs HSPG-mediated varies by context","Downstream mediators validated in single systems"]},{"year":2011,"claim":"Provided the atomic explanation for broad ligand specificity, showing a single membrane-proximal interface recognizes invariant backbone features of TL1A, FasL, and LIGHT.","evidence":"X-ray crystallography of unliganded DcR3 and the TL1A complex with mutagenesis and binding validation","pmids":["21300286"],"confidence":"High","gaps":["FasL and LIGHT complexes not yet crystallized at this stage","Structural basis of HSPG/reverse signaling not addressed"]},{"year":2011,"claim":"Demonstrated context-specific proliferative reverse signaling, with DcR3-FasL engagement driving chondrocyte and synovial fibroblast responses through ERK.","evidence":"Proliferation assays with MEK inhibitor and ligand-blocking antibodies (anti-FasL vs anti-LIGHT/TL1A), and binding assays in RA-FLS","pmids":["21420502","21537832"],"confidence":"Medium","gaps":["RA-FLS finding is Low-confidence/proliferation only","Reconciliation of pro-proliferative vs pro-apoptotic reverse signaling unresolved"]},{"year":2014,"claim":"Completed the structural recognition picture for LIGHT, showing how DcR3 blocks LIGHT engagement of HVEM and LTβR via structure-guided affinity mutants.","evidence":"X-ray crystallography of LIGHT and the LIGHT:DcR3 complex with mutagenesis","pmids":["25087510"],"confidence":"High","gaps":["Functional consequences of designed mutants in vivo not tested"]},{"year":2016,"claim":"Confirmed the FasL:DcR3 interface conforms to the shared recognition paradigm, unifying the structural basis across all three ligands.","evidence":"X-ray crystallography of the FasL:DcR3 complex with Jurkat apoptosis inhibition","pmids":["27806260"],"confidence":"High","gaps":["Does not address oligomeric stoichiometry on cell surfaces"]},{"year":2017,"claim":"Mapped HSPG-dependent reverse signaling onto innate immune restraint, showing DcR3 inactivates PKC-α and activates STK10 to suppress ERK/JNK and limit macrophage and microglial inflammation.","evidence":"Phosphoproteomic mapping, signaling Western blots, DcR3 transgenic mice, HBD.Fc domain experiments, and co-IP of DcR3-HSPG in brain","pmids":["25940317","28438208"],"confidence":"Medium","gaps":["Specific HSPG receptor coupling to STK10 not defined","Single lab for each disease model"]},{"year":2019,"claim":"Established DcR3 as a pro-tumorigenic effector engaging PI3K/AKT/β-catenin, TGF-β3/SMAD, and a STAT1/IRF1 feedback loop to drive EMT, proliferation, and immune escape across multiple cancers.","evidence":"shRNA knockdown and overexpression with pathway Western blots, transcriptional reporters, T-cell differentiation assays, and xenograft models","pmids":["30050309","27764793","31911850","31409774","20597837"],"confidence":"Medium","gaps":["Whether these cancer pathways require ligand decoy vs HSPG engagement is unclear","Each pathway shown in a single tumor type"]},{"year":2024,"claim":"Defined transcriptional control of DcR3, identifying inflammatory NF-κB induction and ZNF37A-mediated promoter repression as upstream regulators relevant to chemoradiation resistance.","evidence":"Selective pathway inhibitors in HUVECs, promoter binding/transcription assays, and shRNA knockdown rescue in colorectal cancer cells","pmids":["30587127","39571490"],"confidence":"Medium","gaps":["Interplay between NF-κB, TGFβ3-Smad-Sp1, and ZNF37A on the promoter not integrated","ZNF37A regulation tested in single tumor context"]},{"year":2013,"claim":"Linked DcR3 dysfunction to autoimmunity, showing patient-derived gain-of-function mutations alter FasL binding kinetics and amplify lymphocyte proliferation.","evidence":"Patient DNA sequencing with recombinant mutant protein binding kinetics and lymphocyte proliferation assays","pmids":["23729807"],"confidence":"Medium","gaps":["Small sample size","Causal contribution to SLE pathogenesis in vivo not established"]},{"year":null,"claim":"It remains unresolved which HSPG receptors and adaptors physically couple DcR3 HSPG engagement to the divergent reverse-signaling outputs (apoptotic vs proliferative vs migration-suppressive) across cell types.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined transmembrane signaling partner for HSPG-mediated reverse signaling","Determinants selecting between opposing reverse-signaling outcomes unknown","Protease responsible for R218-A219 cleavage unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[0,1,2,3,4]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[8,9,10,17]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[9,18,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,3]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,3,7]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,10,15,24]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,3,6,9,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,9,17,21,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[20,21,22,23,27]}],"complexes":[],"partners":["TNFSF14","FASLG","TNFSF15","HSPG2","SDC2","CD44","ITGA4","STK10"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95407","full_name":"Tumor necrosis factor receptor superfamily member 6B","aliases":["Decoy receptor 3","DcR3","Decoy receptor for Fas ligand","M68"],"length_aa":300,"mass_kda":32.7,"function":"Decoy receptor that can neutralize the cytotoxic ligands TNFS14/LIGHT, TNFSF15 and TNFSF6/FASL. Protects against apoptosis","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O95407/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF6B","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF6B","total_profiled":1310},"omim":[{"mim_id":"614587","title":"CHAC GLUTATHIONE-SPECIFIC GAMMA-GLUTAMYLCYCLOTRANSFERASE 1; CHAC1","url":"https://www.omim.org/entry/614587"},{"mim_id":"612566","title":"INFLAMMATORY BOWEL DISEASE 24; IBD24","url":"https://www.omim.org/entry/612566"},{"mim_id":"604052","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 15; TNFSF15","url":"https://www.omim.org/entry/604052"},{"mim_id":"603361","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 6B; TNFRSF6B","url":"https://www.omim.org/entry/603361"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":53.3}],"url":"https://www.proteinatlas.org/search/TNFRSF6B"},"hgnc":{"alias_symbol":["DcR3","DCR3","TR6","M68"],"prev_symbol":[]},"alphafold":{"accession":"O95407","domains":[{"cath_id":"2.10.50.10","chopping":"35-116","consensus_level":"medium","plddt":97.0504,"start":35,"end":116},{"cath_id":"2.10.50.10","chopping":"118-171","consensus_level":"medium","plddt":97.1907,"start":118,"end":171},{"cath_id":"-","chopping":"172-237_249-297","consensus_level":"high","plddt":88.0288,"start":172,"end":297}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95407","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95407-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95407-F1-predicted_aligned_error_v6.png","plddt_mean":86.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF6B","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF6B"},"sequence":{"accession":"O95407","fasta_url":"https://rest.uniprot.org/uniprotkb/O95407.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95407/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95407"}},"corpus_meta":[{"pmid":"11911831","id":"PMC_11911831","title":"TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11911831","citation_count":526,"is_preprint":false},{"pmid":"10318773","id":"PMC_10318773","title":"A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10318773","citation_count":304,"is_preprint":false},{"pmid":"10655513","id":"PMC_10655513","title":"Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10655513","citation_count":187,"is_preprint":false},{"pmid":"11390428","id":"PMC_11390428","title":"Modulation of T-cell responses to alloantigens by TR6/DcR3.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11390428","citation_count":104,"is_preprint":false},{"pmid":"18757243","id":"PMC_18757243","title":"Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.","date":"2008","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/18757243","citation_count":96,"is_preprint":false},{"pmid":"20675196","id":"PMC_20675196","title":"High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis.","date":"2010","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/20675196","citation_count":78,"is_preprint":false},{"pmid":"12740925","id":"PMC_12740925","title":"Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12740925","citation_count":74,"is_preprint":false},{"pmid":"21672030","id":"PMC_21672030","title":"Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions.","date":"2011","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21672030","citation_count":72,"is_preprint":false},{"pmid":"11098089","id":"PMC_11098089","title":"Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas.","date":"2000","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/11098089","citation_count":68,"is_preprint":false},{"pmid":"15002040","id":"PMC_15002040","title":"Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.","date":"2004","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/15002040","citation_count":65,"is_preprint":false},{"pmid":"18006694","id":"PMC_18006694","title":"Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3).","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18006694","citation_count":62,"is_preprint":false},{"pmid":"14500635","id":"PMC_14500635","title":"Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14500635","citation_count":56,"is_preprint":false},{"pmid":"21300286","id":"PMC_21300286","title":"Decoy strategies: the structure of TL1A:DcR3 complex.","date":"2011","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/21300286","citation_count":56,"is_preprint":false},{"pmid":"14871535","id":"PMC_14871535","title":"Quantification and detection of DcR3, a decoy receptor in TNFR family.","date":"2004","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/14871535","citation_count":51,"is_preprint":false},{"pmid":"10632670","id":"PMC_10632670","title":"Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.","date":"2000","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10632670","citation_count":46,"is_preprint":false},{"pmid":"21978578","id":"PMC_21978578","title":"Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease.","date":"2011","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/21978578","citation_count":46,"is_preprint":false},{"pmid":"26099067","id":"PMC_26099067","title":"Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation.","date":"2015","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26099067","citation_count":45,"is_preprint":false},{"pmid":"25887448","id":"PMC_25887448","title":"The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases.","date":"2015","source":"Seminars in arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/25887448","citation_count":39,"is_preprint":false},{"pmid":"11408521","id":"PMC_11408521","title":"In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor.","date":"2001","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11408521","citation_count":39,"is_preprint":false},{"pmid":"27806260","id":"PMC_27806260","title":"Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.","date":"2016","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/27806260","citation_count":38,"is_preprint":false},{"pmid":"30050309","id":"PMC_30050309","title":"DcR3 induces proliferation, migration, invasion, and EMT in gastric cancer cells via the PI3K/AKT/GSK-3β/β-catenin signaling pathway.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30050309","citation_count":36,"is_preprint":false},{"pmid":"19735100","id":"PMC_19735100","title":"DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters.","date":"2009","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/19735100","citation_count":35,"is_preprint":false},{"pmid":"25087510","id":"PMC_25087510","title":"Mechanistic basis for functional promiscuity in the TNF and TNF receptor superfamilies: structure of the LIGHT:DcR3 assembly.","date":"2014","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25087510","citation_count":32,"is_preprint":false},{"pmid":"18723214","id":"PMC_18723214","title":"Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.","date":"2008","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18723214","citation_count":29,"is_preprint":false},{"pmid":"19269042","id":"PMC_19269042","title":"The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid.","date":"2009","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/19269042","citation_count":28,"is_preprint":false},{"pmid":"15215185","id":"PMC_15215185","title":"Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15215185","citation_count":28,"is_preprint":false},{"pmid":"12397645","id":"PMC_12397645","title":"DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer.","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12397645","citation_count":27,"is_preprint":false},{"pmid":"28438208","id":"PMC_28438208","title":"Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model.","date":"2017","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/28438208","citation_count":27,"is_preprint":false},{"pmid":"11907838","id":"PMC_11907838","title":"Ultraviolet light (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes.","date":"2001","source":"Journal of cutaneous medicine and surgery","url":"https://pubmed.ncbi.nlm.nih.gov/11907838","citation_count":26,"is_preprint":false},{"pmid":"18256354","id":"PMC_18256354","title":"IL5RA and TNFRSF6B gene variants are associated with sporadic IgA nephropathy.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/18256354","citation_count":23,"is_preprint":false},{"pmid":"22583667","id":"PMC_22583667","title":"DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.","date":"2012","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22583667","citation_count":23,"is_preprint":false},{"pmid":"12566095","id":"PMC_12566095","title":"Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.","date":"2003","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12566095","citation_count":23,"is_preprint":false},{"pmid":"12941767","id":"PMC_12941767","title":"DcR3/TR6 effectively prevents islet primary nonfunction after transplantation.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12941767","citation_count":22,"is_preprint":false},{"pmid":"21420502","id":"PMC_21420502","title":"DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis.","date":"2011","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/21420502","citation_count":22,"is_preprint":false},{"pmid":"22647538","id":"PMC_22647538","title":"Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis.","date":"2012","source":"Diagnostic microbiology and infectious disease","url":"https://pubmed.ncbi.nlm.nih.gov/22647538","citation_count":22,"is_preprint":false},{"pmid":"20591579","id":"PMC_20591579","title":"TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell.","date":"2010","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/20591579","citation_count":21,"is_preprint":false},{"pmid":"18163957","id":"PMC_18163957","title":"Correlation between expression of DcR3 on tumor cells and sensitivity to FasL.","date":"2007","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18163957","citation_count":21,"is_preprint":false},{"pmid":"27829249","id":"PMC_27829249","title":"DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors.","date":"2016","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27829249","citation_count":21,"is_preprint":false},{"pmid":"12761893","id":"PMC_12761893","title":"DcR3/TR6 modulates immune cell interactions.","date":"2003","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12761893","citation_count":20,"is_preprint":false},{"pmid":"21537832","id":"PMC_21537832","title":"DcR3-TL1A signalling inhibits cytokine-induced proliferation of rheumatoid synovial fibroblasts.","date":"2011","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21537832","citation_count":20,"is_preprint":false},{"pmid":"31409774","id":"PMC_31409774","title":"Role of TGFβ3-Smads-Sp1 axis in DcR3-mediated immune escape of hepatocellular carcinoma.","date":"2019","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31409774","citation_count":20,"is_preprint":false},{"pmid":"22672288","id":"PMC_22672288","title":"Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer.","date":"2012","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22672288","citation_count":19,"is_preprint":false},{"pmid":"20187130","id":"PMC_20187130","title":"Evidence of epistasis between TNFRSF14 and TNFRSF6B polymorphisms in patients with rheumatoid arthritis.","date":"2010","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/20187130","citation_count":18,"is_preprint":false},{"pmid":"24741354","id":"PMC_24741354","title":"Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma.","date":"2014","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/24741354","citation_count":18,"is_preprint":false},{"pmid":"28176915","id":"PMC_28176915","title":"Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis.","date":"2017","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28176915","citation_count":18,"is_preprint":false},{"pmid":"20597837","id":"PMC_20597837","title":"Dcr3 inhibit p53-dependent apoptosis in gamma-irradiated lung cancer cells.","date":"2010","source":"International journal of radiation biology","url":"https://pubmed.ncbi.nlm.nih.gov/20597837","citation_count":18,"is_preprint":false},{"pmid":"27570459","id":"PMC_27570459","title":"Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases.","date":"2016","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27570459","citation_count":17,"is_preprint":false},{"pmid":"28560426","id":"PMC_28560426","title":"DcR3 promotes hepatoma cell migration by downregulating E-cadherin expression.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28560426","citation_count":16,"is_preprint":false},{"pmid":"31911850","id":"PMC_31911850","title":"DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop.","date":"2019","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31911850","citation_count":16,"is_preprint":false},{"pmid":"18376232","id":"PMC_18376232","title":"High DcR3 expression predicts stage pN2-3 in gastric cancer.","date":"2008","source":"American journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18376232","citation_count":16,"is_preprint":false},{"pmid":"27764793","id":"PMC_27764793","title":"DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27764793","citation_count":16,"is_preprint":false},{"pmid":"18562337","id":"PMC_18562337","title":"DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus.","date":"2008","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18562337","citation_count":16,"is_preprint":false},{"pmid":"24101127","id":"PMC_24101127","title":"DcR3 regulates the growth and metastatic potential of SW480 colon cancer cells.","date":"2013","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24101127","citation_count":16,"is_preprint":false},{"pmid":"12878204","id":"PMC_12878204","title":"Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12878204","citation_count":16,"is_preprint":false},{"pmid":"19748482","id":"PMC_19748482","title":"DcR3 protects THP-1 macrophages from apoptosis by increasing integrin alpha4.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19748482","citation_count":15,"is_preprint":false},{"pmid":"36846806","id":"PMC_36846806","title":"A novel promising laccase from the psychrotolerant and halotolerant Antarctic marine Halomonas sp. M68 strain.","date":"2023","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36846806","citation_count":15,"is_preprint":false},{"pmid":"20007581","id":"PMC_20007581","title":"DcR3 protects islet beta cells from apoptosis through modulating Adcyap1 and Bank1 expression.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20007581","citation_count":15,"is_preprint":false},{"pmid":"25940317","id":"PMC_25940317","title":"DcR3 suppresses influenza virus-induced macrophage activation and attenuates pulmonary inflammation and lethality.","date":"2015","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/25940317","citation_count":14,"is_preprint":false},{"pmid":"23449012","id":"PMC_23449012","title":"Expression of TNFRSF6B in kidneys is a novel predictor for progression of chronic kidney disease.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/23449012","citation_count":14,"is_preprint":false},{"pmid":"28223726","id":"PMC_28223726","title":"Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro.","date":"2017","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/28223726","citation_count":14,"is_preprint":false},{"pmid":"27246752","id":"PMC_27246752","title":"Decoy Receptor 3 (DcR3) as a Biomarker of Tumor Deterioration in Female Reproductive Cancers: A Meta-Analysis.","date":"2016","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/27246752","citation_count":13,"is_preprint":false},{"pmid":"21699018","id":"PMC_21699018","title":"Expression of death decoy receptor-3 (DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro.","date":"2011","source":"Journal of experimental therapeutics & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21699018","citation_count":13,"is_preprint":false},{"pmid":"23846297","id":"PMC_23846297","title":"Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo.","date":"2013","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23846297","citation_count":13,"is_preprint":false},{"pmid":"35813013","id":"PMC_35813013","title":"The Role of Decoy Receptor DcR3 in Gastrointestinal Malignancy.","date":"2022","source":"Cancer diagnosis & prognosis","url":"https://pubmed.ncbi.nlm.nih.gov/35813013","citation_count":12,"is_preprint":false},{"pmid":"24040480","id":"PMC_24040480","title":"MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival.","date":"2013","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24040480","citation_count":12,"is_preprint":false},{"pmid":"23817777","id":"PMC_23817777","title":"'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells.","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23817777","citation_count":12,"is_preprint":false},{"pmid":"30537218","id":"PMC_30537218","title":"Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model.","date":"2018","source":"Head & neck","url":"https://pubmed.ncbi.nlm.nih.gov/30537218","citation_count":12,"is_preprint":false},{"pmid":"29311025","id":"PMC_29311025","title":"Effects of miR-340 on hepatocellular carcinoma by targeting the DcR3 gene.","date":"2017","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/29311025","citation_count":11,"is_preprint":false},{"pmid":"29725377","id":"PMC_29725377","title":"The siRNA silencing of DcR3 expression induces Fas ligand-mediated apoptosis in HepG2 cells.","date":"2018","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29725377","citation_count":11,"is_preprint":false},{"pmid":"38986982","id":"PMC_38986982","title":"Protective effects of DcR3-SUMO on lipopolysaccharide-induced inflammatory cells and septic mice.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38986982","citation_count":10,"is_preprint":false},{"pmid":"25823874","id":"PMC_25823874","title":"Absolute quantification of DcR3 and GDF15 from human serum by LC-ESI MS.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25823874","citation_count":10,"is_preprint":false},{"pmid":"19305072","id":"PMC_19305072","title":"Expressions of Fas/DcR3 and RGD-FasL mediated apoptosis in pituitary adenomas.","date":"2009","source":"Neurology India","url":"https://pubmed.ncbi.nlm.nih.gov/19305072","citation_count":10,"is_preprint":false},{"pmid":"22524850","id":"PMC_22524850","title":"Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinomas.","date":"2012","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/22524850","citation_count":10,"is_preprint":false},{"pmid":"27621648","id":"PMC_27621648","title":"Effect of DcR3-specific siRNA on cell growth suppression and apoptosis induction in glioma cells via affecting ERK and AKT.","date":"2016","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27621648","citation_count":10,"is_preprint":false},{"pmid":"33718119","id":"PMC_33718119","title":"TIPE Regulates DcR3 Expression and Function by Activating the PI3K/AKT Signaling Pathway in CRC.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33718119","citation_count":9,"is_preprint":false},{"pmid":"18251184","id":"PMC_18251184","title":"High DcR3 expression predicts stage pN2 in gastric cancer.","date":"2007","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18251184","citation_count":8,"is_preprint":false},{"pmid":"37629097","id":"PMC_37629097","title":"Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37629097","citation_count":7,"is_preprint":false},{"pmid":"12642478","id":"PMC_12642478","title":"Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice.","date":"2003","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/12642478","citation_count":7,"is_preprint":false},{"pmid":"25422191","id":"PMC_25422191","title":"Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25422191","citation_count":7,"is_preprint":false},{"pmid":"26998086","id":"PMC_26998086","title":"Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR3 and ERK1/2.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26998086","citation_count":7,"is_preprint":false},{"pmid":"15814697","id":"PMC_15814697","title":"Tumor vaccine based on cell surface expression of DcR3/TR6.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15814697","citation_count":6,"is_preprint":false},{"pmid":"25997959","id":"PMC_25997959","title":"Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells.","date":"2015","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/25997959","citation_count":6,"is_preprint":false},{"pmid":"18201904","id":"PMC_18201904","title":"Molecular cloning and preliminary expression analysis of banded dogfish (Triakis scyllia) TNF decoy receptor 3 (TNFRSF6B).","date":"2007","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18201904","citation_count":6,"is_preprint":false},{"pmid":"34383195","id":"PMC_34383195","title":"Serum decoy receptor 3 (DcR3): a promising biomarker for atopic asthma in children.","date":"2021","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/34383195","citation_count":6,"is_preprint":false},{"pmid":"31122523","id":"PMC_31122523","title":"Low plasma levels of decoy receptor 3 (DcR3) in the third trimester of pregnancy with preeclampsia.","date":"2019","source":"Taiwanese journal of obstetrics & gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/31122523","citation_count":6,"is_preprint":false},{"pmid":"29552282","id":"PMC_29552282","title":"Identification and preclinical evaluation of the small molecule, NSC745887, for treating glioblastomas via suppressing DcR3-associated signaling pathways.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29552282","citation_count":6,"is_preprint":false},{"pmid":"21293109","id":"PMC_21293109","title":"Expression of DcR3 and its effects in kaposi's sarcoma-associated herpesvirus-infected human endothelial cells.","date":"2011","source":"Intervirology","url":"https://pubmed.ncbi.nlm.nih.gov/21293109","citation_count":5,"is_preprint":false},{"pmid":"30587127","id":"PMC_30587127","title":"Up-regulation of DcR3 in microbial toxins-stimulated HUVECs involves NF-κB signalling.","date":"2018","source":"BMC biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30587127","citation_count":5,"is_preprint":false},{"pmid":"39604254","id":"PMC_39604254","title":"Dual Responsive Magnetic DCR3 Nanoparticles: A New Strategy for Efficiently Targeting Hepatocellular Carcinoma.","date":"2024","source":"Small (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39604254","citation_count":5,"is_preprint":false},{"pmid":"26176090","id":"PMC_26176090","title":"Promotive Effects of Dcr3 Gene on the Occurrence and Progression of Gastric Cancer and its Mechanism.","date":"2014","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26176090","citation_count":5,"is_preprint":false},{"pmid":"34824540","id":"PMC_34824540","title":"The Network of Pro-Inflammatory Factors CD147, DcR3, and IL33 in the Development of Kawasaki Disease.","date":"2021","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/34824540","citation_count":5,"is_preprint":false},{"pmid":"34394787","id":"PMC_34394787","title":"When Cultures Fail: Postmortem Decoy Receptor 3 (DcR3) as a Marker of Antemortem Sepsis.","date":"2019","source":"Academic forensic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34394787","citation_count":5,"is_preprint":false},{"pmid":"20969926","id":"PMC_20969926","title":"Administration of dendritic cells dual expressing DcR3 and GAD65 mediates the suppression of T cells and induces long-term acceptance of pancreatic-islet transplantation.","date":"2010","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/20969926","citation_count":5,"is_preprint":false},{"pmid":"39571490","id":"PMC_39571490","title":"ZNF37A downregulation promotes TNFRSF6B expression and leads to therapeutic resistance to concurrent chemoradiotherapy in rectal cancer patients.","date":"2024","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39571490","citation_count":4,"is_preprint":false},{"pmid":"27517320","id":"PMC_27517320","title":"DcR3 gene polymorphisms are associated with sporadic breast infiltrating ductal carcinoma in Northeast Chinese women.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27517320","citation_count":4,"is_preprint":false},{"pmid":"23729807","id":"PMC_23729807","title":"DcR3 mutations in patients with juvenile-onset systemic lupus erythematosus lead to enhanced lymphocyte proliferation.","date":"2013","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/23729807","citation_count":4,"is_preprint":false},{"pmid":"31332995","id":"PMC_31332995","title":"Association of Tumor Necrosis Like factor 1 A (TL1A) and its Decoy Receptor (DcR3) with The Disease Activity and Autoantibody Production in Rheumatoid Arthritis Patients.","date":"2019","source":"The Egyptian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31332995","citation_count":4,"is_preprint":false},{"pmid":"34532119","id":"PMC_34532119","title":"Integrative analysis of TNFRSF6B as a potential therapeutic target for pancreatic cancer.","date":"2021","source":"Journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34532119","citation_count":3,"is_preprint":false},{"pmid":"23245480","id":"PMC_23245480","title":"High serum DcR3 levels are associated with the occurrence of peritonitis in patients receiving chronic peritoneal dialysis.","date":"2012","source":"Journal of the Chinese Medical Association : JCMA","url":"https://pubmed.ncbi.nlm.nih.gov/23245480","citation_count":3,"is_preprint":false},{"pmid":"29296192","id":"PMC_29296192","title":"DcR3 combined with hematological traits serves as a valuable biomarker for the diagnosis of cancer metastasis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29296192","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53068,"output_tokens":7646,"usd":0.136947,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17126,"output_tokens":5266,"usd":0.10864,"stage2_stop_reason":"end_turn"},"total_usd":0.245587,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"TR6/DcR3 specifically binds two TNF-family ligands, LIGHT and FasL/CD95L, as demonstrated by immunoprecipitation with histidine-tagged recombinant TR6 and confirmed by flow cytometry on LIGHT-transfected HEK 293 EBNA cells. TR6 inhibits LIGHT-induced cytotoxicity in HT29 cells by blocking LIGHT interactions with HVEM/TR2 and LTβR.\",\n      \"method\": \"Immunoprecipitation, flow cytometry, cytotoxicity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding confirmed by two orthogonal methods (IP and flow cytometry), functional inhibition demonstrated, replicated in multiple cell lines\",\n      \"pmids\": [\"10318773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TL1A is a third ligand for DcR3/TR6 (and for signaling receptor DR3). TR6-Fc protein binds TL1A and antagonizes TL1A-induced NF-κB activation and apoptosis in DR3-expressing cell lines, demonstrating DcR3 decoy function against TL1A.\",\n      \"method\": \"Ligand binding assay, NF-κB reporter assay, apoptosis assay, TR6-Fc competition\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional antagonism demonstrated by multiple assays, TR6-Fc competition confirms direct ligand neutralization\",\n      \"pmids\": [\"11911831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TR6-Fc recombinant protein binds human LIGHT expressed on 293 cells or activated T cells and competes with the LIGHT receptor TR2 for LIGHT binding, as shown by flow cytometry and immunoprecipitation. TR6 downregulates CTL activity and modulates lymphokine production in vitro and in vivo.\",\n      \"method\": \"Flow cytometry, immunoprecipitation, CTL assay, graft-versus-host mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (flow cytometry, IP, in vivo model) confirming competitive antagonism of LIGHT:TR2 interaction\",\n      \"pmids\": [\"11390428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TR6 binds FasL and blocks FasL-mediated cell killing in vitro in multiple cell systems (human hepatocytes, HT-29, Jurkat cells) and in vivo in a mouse fulminant hepatitis model where pretreatment with TR6 blocked FasL-induced mortality. Human TR6 cross-reacts with membrane-bound mouse FasL. Binding of human TR6 to human FasL was confirmed by BIAcore surface plasmon resonance.\",\n      \"method\": \"BIAcore binding assay, cytotoxicity assays, in vivo mouse hepatitis model\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding measured by SPR, functional inhibition in multiple cell systems and confirmed in vivo\",\n      \"pmids\": [\"11408521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of unliganded DcR3 ectodomain and its complex with TL1A reveals that DcR3 interacts with invariant backbone and side-chain atoms in the membrane-proximal half of TL1A. Mutagenesis and biochemical studies show that the same interface supports recognition of FasL, LIGHT, and TL1A, while antideterminant features prevent binding to other TNF superfamily members. This is a unique mode of TNF:TNFR interaction enabling broad ligand specificity.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, biochemical binding assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure combined with mutagenesis and biochemical validation, mechanistically defines the basis for DcR3 multi-ligand recognition\",\n      \"pmids\": [\"21300286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal structure of LIGHT and the LIGHT:DcR3 complex reveals the structural basis for DcR3-mediated neutralization of LIGHT and its inhibition of LIGHT interactions with HVEM and LTβR. Structure-guided LIGHT mutants with altered affinities for DcR3 and HVEM were generated, validating the binding interface.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, binding affinity assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure with mutagenesis validation, mechanistically defining LIGHT:DcR3 binding mode\",\n      \"pmids\": [\"25087510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structure of FasL in complex with DcR3 reveals that DcR3 recognizes invariant main-chain and conserved side-chain functionalities of FasL, consistent with the recognition paradigm seen in TL1A:DcR3 and LIGHT:DcR3 structures. Recombinant DcR3 efficiently inhibits FasL-induced Jurkat cell apoptosis.\",\n      \"method\": \"X-ray crystallography, apoptosis assay\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure with functional validation of FasL:DcR3 inhibition of apoptosis\",\n      \"pmids\": [\"27806260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"DcR3 is proteolytically cleaved between R218 and A219 (identified by mass spectrometry and N-terminal sequencing) to yield DcR3(1–218), which retains LIGHT-binding activity but loses FasL-binding ability. Engineering of R218Q substitution (FLINT/LY498919) prevents proteolytic cleavage and restores activity against both FasL and LIGHT in vitro and in vivo.\",\n      \"method\": \"Mass spectrometry, N-terminal sequencing, in vitro binding assay, site-directed mutagenesis, in vivo pharmacokinetic study\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry identification of cleavage site, mutagenesis rescue, confirmed in vitro and in vivo; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"12566095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DcR3 induces osteoclast formation from human monocytes, murine RAW264.7 macrophages, and bone marrow cells via 'reverse signaling'. DcR3-differentiated cells exhibit osteoclast characteristics (polynuclear morphology, bone resorption, TRAP, CD51/61, MMP-9). DcR3 treatment induces TNF-α release through ERK and p38 MAPK signaling; the osteoclastogenic effect is abrogated by TNFR-Fc, confirming TNF-α as the downstream mediator.\",\n      \"method\": \"Cell differentiation assay, bone resorption assay, Western blotting for MAPK signaling, TNFR-Fc blocking experiment\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean loss-of-function (blocking) with specific phenotypic readout and pathway placement (ERK/p38 → TNF-α → osteoclastogenesis), single lab\",\n      \"pmids\": [\"15002040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"DcR3 induces apoptosis in dendritic cells by binding heparan sulfate proteoglycans (HSPG) on DCs via its heparin-binding domain (HBD), activating PKC-δ and JNK, upregulating DR5, and recruiting FADD to form a death-inducing signaling complex (DISC). HBD.Fc fusion protein alone recapitulates this effect, demonstrating that HSPG cross-linking is sufficient to trigger the apoptotic cascade.\",\n      \"method\": \"Apoptosis assay, Western blotting (PKC-δ, JNK, DR5, FADD), DISC immunoprecipitation, HBD.Fc domain dissection experiment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — DISC co-IP, domain dissection with HBD.Fc, multiple downstream signaling nodes validated, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"18006694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TR6/DcR3 inhibits T cell chemotaxis toward CXCL12/SDF-1α in vitro and in vivo. Solid-phase TR6-Fc or anti-LIGHT mAb similarly inhibit chemotaxis, implicating LIGHT reverse signaling. Mechanistically, TR6 pretreatment prevents Cdc42 activation, p38 MAPK phosphorylation, actin polymerization, and pseudopodium formation in T cells.\",\n      \"method\": \"Transwell chemotaxis assay, Cdc42 activation assay, p38 MAPK phosphorylation assay, actin polymerization assay, in vivo mouse chemotaxis model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal mechanistic readouts (Cdc42, p38, actin, pseudopodium) with in vivo confirmation, single lab\",\n      \"pmids\": [\"14500635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TR6 secreted by PBMC inhibits actin polymerization and pseudopodium formation in T cells upon mitogen stimulation, suppressing T cell aggregation induced by alloantigens, anti-CD3, or PHA in a soluble or solid-phase manner.\",\n      \"method\": \"Actin polymerization assay, T cell aggregation assay (PBMC stimulation with alloantigens/anti-CD3/PHA), TR6-Fc solid-phase treatment\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple aggregation assays, actin polymerization measured, single lab, complementary to PMID 14500635\",\n      \"pmids\": [\"12761893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DcR3 protects beta islet cells from apoptosis induced by FasL, LIGHT, and TL1A. DNA microarray analysis of DcR3 transgenic islets revealed that Adcyap1 is upregulated >700-fold and Bank1 is downregulated 50-fold after cytokine assault. Forced overexpression of Adcyap1 or knockdown of Bank1 in insulinoma NIT-1 cells each independently protected against cytokine-triggered apoptosis, identifying novel downstream mediators.\",\n      \"method\": \"DNA microarray, transgenic mouse model, siRNA knockdown, plasmid overexpression, apoptosis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DNA microarray combined with functional validation (siRNA + overexpression) for downstream mediators, single lab\",\n      \"pmids\": [\"20007581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DcR3-Fc protects THP-1 macrophages from apoptosis by upregulating integrin α4 (VLA-4), promoting macrophage aggregate formation. Anti-VLA4 antibody blocks both the anti-apoptotic effect and aggregate formation induced by DcR3-Fc, demonstrating that increased α4 integrin expression is the mechanism of DcR3-mediated macrophage survival.\",\n      \"method\": \"Apoptosis assay (CHX-induced), integrin expression by Western blot/flow cytometry, anti-VLA4 antibody blocking experiment, aggregate formation assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody blocking confirms mechanistic link between DcR3, α4 integrin upregulation, and anti-apoptotic effect; single lab\",\n      \"pmids\": [\"19748482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DcR3 binds to TL1A expressed on rheumatoid synovial fibroblasts (RA-FLS) and negatively regulates cytokine-induced cell proliferation. This DcR3-TL1A signaling represents a 'reverse signaling' mode where DcR3 acts as a ligand rather than a decoy receptor.\",\n      \"method\": \"Cell proliferation assay, binding assay in RA-FLS, cytokine stimulation experiments\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, limited mechanistic depth in abstract, proliferation assay alone\",\n      \"pmids\": [\"21537832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DcR3 suppresses Th17 immune responses; DcR3.Fc treatment of PLP-specific lymph node cells suppresses IFN-γ and IL-17 production and reduces proportion of Th17 cells. DcR3.Fc treatment of CD4+ T cells with defective FasL did not suppress IL-17, demonstrating that DcR3-mediated IL-17 suppression depends on disruption of Fas-FasL interactions.\",\n      \"method\": \"Lymph node cell culture, cytokine ELISA, flow cytometry (Th17 proportion), FasL-defective T cell experiment\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FasL-defective T cell control establishes mechanism; multiple assays; single lab\",\n      \"pmids\": [\"19269042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DcR3 inhibits p53-dependent apoptosis in lung cancer cells. Knockdown of DcR3 in p53-expressing cells sensitizes them to γ-irradiation by inducing p53-dependent Fas-mediated apoptosis pathway. In p53-deficient H1299 cells, DcR3 knockdown had no effect on survival after irradiation, but introduction of p53 restored sensitivity. Overexpression of DcR3 increased survival of radiosensitive cells.\",\n      \"method\": \"siRNA knockdown, clonogenic survival assay, p53 re-introduction experiment, Western blot\",\n      \"journal\": \"International journal of radiation biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established via p53-null vs. p53-rescue experiment, multiple cell lines tested; single lab\",\n      \"pmids\": [\"20597837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DcR3 attenuates influenza A virus-induced macrophage activation by inactivating PKC-α and activating STK10 (a negative regulator of cell migration), thereby suppressing ERK and JNK activation. Proteome-wide phosphoproteomic mapping identified these kinase targets. DcR3-transgenic mice show reduced pulmonary infiltration and cytokine levels, and recombinant HBD.Fc (heparin-binding domain of DcR3) recapitulates protection, indicating HSPG-dependent signaling.\",\n      \"method\": \"Phosphoproteomic mapping, Western blot (ERK, JNK, PKC-α, STK10), DcR3 transgenic mouse, HBD.Fc domain experiment\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomic mapping with in vivo transgenic confirmation and HBD.Fc domain dissection; single lab\",\n      \"pmids\": [\"25940317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DcR3 mediates neuroprotection in an Alzheimer's disease model by interacting with heparan sulfate proteoglycans (HSPGs) and activating IL-4+YM1+ M2a-like microglia, reducing Aβ-induced proinflammatory cytokines and promoting phagocytosis. Co-immunoprecipitation confirmed DcR3-HSPG interaction in brain tissue of APP/DcR3 transgenic mice.\",\n      \"method\": \"APP/DcR3 transgenic mouse cross, immunostaining, ELISA, qPCR, immunoprecipitation (DcR3-HSPG), in vitro macrophage polarization assay\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IP confirms HSPG interaction in vivo, multiple readouts (behavioral, pathological, molecular); single lab\",\n      \"pmids\": [\"28438208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"DcR3 binds to epithelial ovarian cancer cells via heparan sulfate proteoglycans (HSPGs); binding is inhibited by heparin and heparinase treatment. DcR3 binding via HSPGs (Syndecan-2 and CD44v3) alters platinum chemotherapy responsiveness and modulates BRCA1 expression (increase in SKOV-3/OVCAR-3, decrease in CaOV3), affecting DNA repair pathways.\",\n      \"method\": \"Heparin/heparinase competition binding assay, RT-PCR array, Western blot (BRCA1), MTT cell viability assay\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic binding inhibition with heparin/heparinase validates HSPG-dependent interaction; BRCA1 confirmed by Western blot; single lab\",\n      \"pmids\": [\"22583667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Missense mutations in DcR3 (T56I and H122Y) identified in SLE patients exhibit altered binding kinetics to FasL and significantly increase lymphocyte proliferation compared to wild-type DcR3 protein, demonstrating gain-of-function mutations that perturb receptor-ligand interaction.\",\n      \"method\": \"DNA sequencing, recombinant mutant protein production, FasL binding kinetics assay, lymphocyte proliferation assay\",\n      \"journal\": \"The Journal of rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — recombinant protein mutagenesis with binding kinetics and functional readout; single lab, limited sample size\",\n      \"pmids\": [\"23729807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DcR3 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of gastric cancer cells via the PI3K/AKT/GSK-3β/β-catenin signaling pathway. DcR3 knockdown reduces p-AKT, p-GSK-3β, and β-catenin levels; DcR3 enhances N-cadherin and Vimentin expression while decreasing E-cadherin.\",\n      \"method\": \"shRNA stable knockdown, proliferation/invasion/migration assays, Western blot (PI3K/AKT pathway components, EMT markers)\",\n      \"journal\": \"OncoTargets and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable shRNA knockdown with multiple functional assays and pathway Western blots; single lab\",\n      \"pmids\": [\"30050309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DcR3 is essential for TGF-β3/SMAD-mediated epithelial-mesenchymal transition (EMT) in colorectal cancer cells. DcR3 overexpression enhances CRC proliferation and migration in vitro and tumorigenesis in vivo; DcR3 knockdown attenuates CRC tumorigenesis and metastasis in vivo. DcR3 expression correlates with TGF-β3/SMAD-EMT signaling components.\",\n      \"method\": \"shRNA knockdown, DcR3 overexpression, in vitro proliferation/migration assays, in vivo xenograft model, Western blot (SMAD pathway, EMT markers)\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional genetic manipulation (KD and OE), in vivo confirmation, pathway Western blots; single lab\",\n      \"pmids\": [\"27764793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DcR3 promotes pancreatic cancer proliferation and invasion through a positive feedback loop: DcR3 activates STAT1 phosphorylation, leading to increased IRF1, which then increases DcR3 transcriptional activity. DcR3 also promotes CEACAM1 expression through activated IRF1.\",\n      \"method\": \"Loss-of-function and gain-of-function experiments, Western blot (STAT1 phosphorylation, IRF1), transcriptional reporter assay, in vitro proliferation/invasion assays, in vivo tumor growth assay\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional genetic manipulation, transcriptional reporter confirms feedback loop, in vivo confirmation; single lab\",\n      \"pmids\": [\"31911850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DcR3 overexpression in hepatocellular carcinoma is mediated by the TGFβ3-Smad-Sp1 signaling pathway, which directly targets DcR3 promoter regions. DcR3 overexpression promotes Th2 and Treg cell differentiation while inhibiting Th1 cell differentiation; DcR3 knockdown restores CD4+ T cell immunity.\",\n      \"method\": \"Promoter analysis, ChIP/reporter assay (TGFβ3-Smad-Sp1 targeting DcR3 promoter), T cell differentiation assays, DcR3 knockdown and overexpression\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter targeting validated, T cell functional assays; single lab, limited method detail in abstract\",\n      \"pmids\": [\"31409774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DcR3 promotes hepatoma cell migration by downregulating E-cadherin expression and activating NF-κB signaling (IκBα degradation and p65 nuclear translocation). DcR3 expression inversely correlates with E-cadherin expression in liver cancer tissues.\",\n      \"method\": \"Immunofluorescence, flow cytometry, Western blot (E-cadherin, IκBα, p65), immunohistochemistry of clinical samples\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple methods but largely correlative; NF-κB activation shown by Western blot without definitive causal rescue experiment\",\n      \"pmids\": [\"28560426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Up-regulation of DcR3 by microbial toxins (LPS, LTA, zymosan) in HUVECs proceeds through the NF-κB signaling pathway; NF-κB inhibitor PDTC decreased DcR3 expression, while JNK (SP600125) and p38 MAPK (SB203580) inhibitors had no effect on DcR3 mRNA or protein levels.\",\n      \"method\": \"RT-PCR, ELISA, pharmacological pathway inhibition (PDTC, SP600125, SB203580)\",\n      \"journal\": \"BMC biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway specificity confirmed by selective inhibitors, negative controls (JNK/p38 inhibitors) establish specificity for NF-κB; single lab\",\n      \"pmids\": [\"30587127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZNF37A binds to the TNFRSF6B/DcR3 promoter region and suppresses its transcriptional activity. Reduced ZNF37A expression induces chemoradiation resistance by inhibiting apoptosis in colorectal cancer cells; TNFRSF6B knockdown restores sensitivity to chemoradiotherapy.\",\n      \"method\": \"Promoter binding assay, transcriptional activity assay, shRNA knockdown, genome-wide expression profiling, functional apoptosis/survival assays\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding and transcriptional repression demonstrated, functional rescue by TNFRSF6B knockdown; single lab\",\n      \"pmids\": [\"39571490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DcR3 induces chondrocyte proliferation in osteoarthritis chondrocytes via ERK (MAPK) signaling specifically. DcR3-Fc-induced proliferation is blocked by MEK1/2 inhibitor PD098059 and by anti-FasL blocking antibody, but not by anti-LIGHT or anti-TL1A antibodies, establishing that the proliferative effect is mediated through DcR3 binding to FasL and ERK activation.\",\n      \"method\": \"WST proliferation assay, Western blot (ERK, p38, JNK phosphorylation), MEK inhibitor, ligand-blocking antibodies, TUNEL/caspase Western blot (apoptosis)\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitor and blocking antibody experiments establish pathway specificity; single lab\",\n      \"pmids\": [\"21420502\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DcR3/TNFRSF6B is a secreted, soluble decoy receptor that lacks transmembrane and death domains; it neutralizes three TNF-family ligands (FasL, LIGHT, and TL1A) by competitively binding their membrane-proximal interface (established by crystal structures of all three complexes), thereby blocking apoptosis, T-cell activation, and immune responses mediated by these ligands. Beyond decoy function, DcR3 engages heparan sulfate proteoglycans (HSPGs) on target cells to trigger 'reverse signaling'—activating PKC-δ/JNK in dendritic cells to induce DR5-FADD DISC formation and apoptosis, or activating ERK/p38 MAPK in monocytes to drive osteoclastogenesis via TNF-α, or activating STK10/inhibiting PKC-α to suppress macrophage migration; in T cells, DcR3 prevents Cdc42 activation and actin polymerization to inhibit chemotaxis and aggregation; in cancer cells, it engages PI3K/AKT/GSK-3β/β-catenin, TGF-β3/SMAD, and STAT1/IRF1 pathways to promote EMT, proliferation, and immune escape, with its own expression regulated by NF-κB, TGFβ3-Smad-Sp1, and the STAT1/IRF1 feedback loop. Proteolytic cleavage at R218-A219 generates a fragment that retains LIGHT binding but loses FasL binding, and the R218Q mutation (FLINT) stabilizes the intact molecule.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFRSF6B (DcR3/TR6) is a secreted soluble decoy receptor of the TNF receptor superfamily that neutralizes three TNF-family ligands—FasL/CD95L, LIGHT, and TL1A—to dampen apoptosis, cytotoxic T-cell activity, and inflammatory signaling [#0, #1, #2, #3]. Crystal structures of DcR3 bound to TL1A, LIGHT, and FasL show that it engages invariant main-chain and conserved side-chain atoms in the membrane-proximal half of each ligand, a single shared interface that explains its broad specificity while antideterminants exclude other TNF superfamily members [#4, #5, #6]; in functional terms this lets DcR3-Fc competitively block LIGHT binding to HVEM/TR2 and LTβR, antagonize TL1A-induced NF-κB activation and DR3 apoptosis, and inhibit FasL-mediated killing in vitro and in vivo [#0, #1, #3]. Proteolytic cleavage between R218 and A219 yields a fragment that retains LIGHT binding but loses FasL binding, and the R218Q (FLINT) substitution blocks cleavage to preserve activity against both ligands [#7]. Beyond decoy function, DcR3 acts as a ligand that engages heparan sulfate proteoglycans on target cells to trigger 'reverse signaling': HSPG cross-linking by its heparin-binding domain activates PKC-δ/JNK to upregulate DR5 and assemble a FADD-containing DISC in dendritic cells, drives ERK/p38-dependent TNF-α release to promote osteoclastogenesis in monocytes, and modulates macrophage and microglial activation [#8, #9, #17, #18]. In T cells DcR3/LIGHT reverse signaling blocks Cdc42 activation, p38 phosphorylation, and actin polymerization to suppress chemotaxis and aggregation [#10, #11]. In cancer, DcR3 promotes proliferation, migration, and EMT through PI3K/AKT/GSK-3β/β-catenin, TGF-β3/SMAD, and a self-reinforcing STAT1/IRF1 loop, and its own expression is controlled by NF-κB, TGFβ3-Smad-Sp1, and transcriptional repression by ZNF37A [#21, #22, #23, #24, #26, #27]. Gain-of-function DcR3 missense mutations (T56I, H122Y) with altered FasL binding and increased lymphocyte proliferation have been identified in SLE patients [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established DcR3 as a soluble decoy that binds TNF-family ligands rather than transducing signal, by showing it captures LIGHT and FasL and neutralizes LIGHT cytotoxicity.\",\n      \"evidence\": \"Immunoprecipitation, flow cytometry on LIGHT-transfected cells, and cytotoxicity blockade in HT29 cells\",\n      \"pmids\": [\"10318773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of multi-ligand recognition\", \"TL1A not yet identified as a ligand\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the competitive mechanism against LIGHT and FasL and demonstrated immunological consequences, showing DcR3 displaces LIGHT from TR2 and blocks FasL-induced killing in vivo.\",\n      \"evidence\": \"Flow cytometry/IP competition with TR2, BIAcore SPR for FasL binding, CTL assays, and mouse GvHD and fulminant hepatitis models\",\n      \"pmids\": [\"11390428\", \"11408521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic interface not yet defined\", \"Whether one binding site accommodates all ligands unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified TL1A as a third DcR3 ligand and showed DcR3-Fc antagonizes TL1A-driven NF-κB and apoptosis via the DR3 axis, expanding the decoy's ligand repertoire.\",\n      \"evidence\": \"Ligand binding, NF-κB reporter and apoptosis assays with TR6-Fc competition in DR3-expressing lines\",\n      \"pmids\": [\"11911831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address reverse signaling through TL1A on ligand-bearing cells\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealed that proteolytic cleavage at R218-A219 differentially abolishes FasL but not LIGHT binding, and that the R218Q mutation stabilizes the intact, dually active molecule—pharmacologically relevant for the FLINT therapeutic.\",\n      \"evidence\": \"Mass spectrometry, N-terminal sequencing, mutagenesis rescue, and in vivo pharmacokinetics\",\n      \"pmids\": [\"12566095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the responsible protease not established\", \"Physiological context regulating cleavage unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Established that DcR3 acts as a ligand triggering reverse signaling in T cells, suppressing chemotaxis and aggregation by blocking Cdc42, p38, and actin polymerization.\",\n      \"evidence\": \"Transwell chemotaxis, Cdc42 activation, p38 phosphorylation, actin polymerization assays with anti-LIGHT mAb and in vivo chemotaxis model\",\n      \"pmids\": [\"14500635\", \"12761893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor on T cells mediating reverse signaling not fully defined\", \"Link between LIGHT engagement and Cdc42 inhibition incomplete\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined HSPG cross-linking by the heparin-binding domain as a decoy-independent mechanism, showing DcR3 induces DC apoptosis via PKC-δ/JNK, DR5 upregulation, and FADD-DISC formation.\",\n      \"evidence\": \"DISC co-IP, signaling Western blots, and HBD.Fc domain-dissection apoptosis assays\",\n      \"pmids\": [\"18006694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HSPG species engaged in DCs not identified\", \"How HSPG binding activates PKC-δ mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed DcR3 reverse signaling drives osteoclastogenesis, placing ERK/p38-induced TNF-α as the downstream effector of monocyte differentiation.\",\n      \"evidence\": \"Differentiation and bone resorption assays, MAPK Western blots, and TNFR-Fc blockade\",\n      \"pmids\": [\"15002040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor coupling ERK/p38 to TNF-α not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended DcR3 cytoprotection to islet, macrophage, and Th17 contexts, identifying distinct effectors (Adcyap1/Bank1, α4 integrin) and confirming FasL-dependence of IL-17 suppression.\",\n      \"evidence\": \"Transgenic islet microarray with siRNA/overexpression validation, anti-VLA4 blocking in macrophages, and FasL-defective T-cell controls\",\n      \"pmids\": [\"20007581\", \"19748482\", \"19269042\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether effects are decoy- vs HSPG-mediated varies by context\", \"Downstream mediators validated in single systems\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided the atomic explanation for broad ligand specificity, showing a single membrane-proximal interface recognizes invariant backbone features of TL1A, FasL, and LIGHT.\",\n      \"evidence\": \"X-ray crystallography of unliganded DcR3 and the TL1A complex with mutagenesis and binding validation\",\n      \"pmids\": [\"21300286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FasL and LIGHT complexes not yet crystallized at this stage\", \"Structural basis of HSPG/reverse signaling not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated context-specific proliferative reverse signaling, with DcR3-FasL engagement driving chondrocyte and synovial fibroblast responses through ERK.\",\n      \"evidence\": \"Proliferation assays with MEK inhibitor and ligand-blocking antibodies (anti-FasL vs anti-LIGHT/TL1A), and binding assays in RA-FLS\",\n      \"pmids\": [\"21420502\", \"21537832\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RA-FLS finding is Low-confidence/proliferation only\", \"Reconciliation of pro-proliferative vs pro-apoptotic reverse signaling unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Completed the structural recognition picture for LIGHT, showing how DcR3 blocks LIGHT engagement of HVEM and LTβR via structure-guided affinity mutants.\",\n      \"evidence\": \"X-ray crystallography of LIGHT and the LIGHT:DcR3 complex with mutagenesis\",\n      \"pmids\": [\"25087510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of designed mutants in vivo not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Confirmed the FasL:DcR3 interface conforms to the shared recognition paradigm, unifying the structural basis across all three ligands.\",\n      \"evidence\": \"X-ray crystallography of the FasL:DcR3 complex with Jurkat apoptosis inhibition\",\n      \"pmids\": [\"27806260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address oligomeric stoichiometry on cell surfaces\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Mapped HSPG-dependent reverse signaling onto innate immune restraint, showing DcR3 inactivates PKC-α and activates STK10 to suppress ERK/JNK and limit macrophage and microglial inflammation.\",\n      \"evidence\": \"Phosphoproteomic mapping, signaling Western blots, DcR3 transgenic mice, HBD.Fc domain experiments, and co-IP of DcR3-HSPG in brain\",\n      \"pmids\": [\"25940317\", \"28438208\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific HSPG receptor coupling to STK10 not defined\", \"Single lab for each disease model\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established DcR3 as a pro-tumorigenic effector engaging PI3K/AKT/β-catenin, TGF-β3/SMAD, and a STAT1/IRF1 feedback loop to drive EMT, proliferation, and immune escape across multiple cancers.\",\n      \"evidence\": \"shRNA knockdown and overexpression with pathway Western blots, transcriptional reporters, T-cell differentiation assays, and xenograft models\",\n      \"pmids\": [\"30050309\", \"27764793\", \"31911850\", \"31409774\", \"20597837\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these cancer pathways require ligand decoy vs HSPG engagement is unclear\", \"Each pathway shown in a single tumor type\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined transcriptional control of DcR3, identifying inflammatory NF-κB induction and ZNF37A-mediated promoter repression as upstream regulators relevant to chemoradiation resistance.\",\n      \"evidence\": \"Selective pathway inhibitors in HUVECs, promoter binding/transcription assays, and shRNA knockdown rescue in colorectal cancer cells\",\n      \"pmids\": [\"30587127\", \"39571490\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay between NF-κB, TGFβ3-Smad-Sp1, and ZNF37A on the promoter not integrated\", \"ZNF37A regulation tested in single tumor context\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked DcR3 dysfunction to autoimmunity, showing patient-derived gain-of-function mutations alter FasL binding kinetics and amplify lymphocyte proliferation.\",\n      \"evidence\": \"Patient DNA sequencing with recombinant mutant protein binding kinetics and lymphocyte proliferation assays\",\n      \"pmids\": [\"23729807\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small sample size\", \"Causal contribution to SLE pathogenesis in vivo not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved which HSPG receptors and adaptors physically couple DcR3 HSPG engagement to the divergent reverse-signaling outputs (apoptotic vs proliferative vs migration-suppressive) across cell types.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined transmembrane signaling partner for HSPG-mediated reverse signaling\", \"Determinants selecting between opposing reverse-signaling outcomes unknown\", \"Protease responsible for R218-A219 cleavage unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [8, 9, 10, 17]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [9, 18, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 3, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 10, 15, 24]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 3, 6, 9, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 9, 17, 21, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [20, 21, 22, 23, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TNFSF14\", \"FASLG\", \"TNFSF15\", \"HSPG2\", \"SDC2\", \"CD44\", \"ITGA4\", \"STK10\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}